ArticleFrontiers in pharmacology2022
Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS).
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLUOphthalmology and therapy · 2026Article
- Understanding anti-vascular endothelial growth factor medications: chemical properties, costs, and side effects.Journal of medicine and life · 2026Review
- Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events.Journal of clinical pharmacology · 2026Article
- Adverse event reporting patterns of rituximab and obinutuzumab in B-cell non-Hodgkin lymphoma: a FAERS pharmacovigilance study.Frontiers in immunology · 2026Article
- Endothelial-to-mesenchymal transition in the central nervous system: A potential therapeutic target to combat age-related vascular fragility.The Journal of pharmacology and experimental therapeutics · 2025Review
- A Personal Scientific Journey in Ophthalmology: Twenty-Five Years of Translating Research into Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.Breast cancer research : BCR · 2025Article
- Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series.BMC ophthalmology · 2025Article
- To Treat or Not to Treat? Resolving the Question of Subretinal and Intraretinal Fluid in Age-Related Macular Degeneration: A Narrative Review.Ophthalmology and therapy · 2025Review
- Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2025Article
- Global trends and hotspots of inflammation in diabetic retinopathy: a literature review and bibliometric analysis.Frontiers in medicine · 2025Review
- Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Mechanistic insights into modified Danggui Buxue Decoction for diabetic retinopathy via integrative analysis.Frontiers in endocrinology · 2025Article
- Retinal Artery Occlusion: A Review of Current Management Practices.Journal of ophthalmic & vision research · 2024Review
- Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis.International ophthalmology · 2024Review
- Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.BMC pharmacology & toxicology · 2024Article
- Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study.Frontiers in pharmacology · 2024Article
- A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study.Frontiers in pharmacology · 2024Article
- Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.